Is it a 3 Musketeers Scenario?
Will Contrave Vote Bode Well for All Obesity Drugmakers?
By Donna Young
Thursday, December 9, 2010
WASHINGTON Investors in Orexigen Therapeutics Inc. Wednesday were not only bubbling over with excitement about an FDA panel's backing of the firm's obesity drug Contrave (naltrexone/bupropion) with the company's stock rocketing as high as 129 percent but shares of potential competitors Arena Pharmaceuticals Inc. and Vivus Inc. also were on fire, leaping as high as 20.5 percent and 19.5 percent, respectively.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.